Posted on May 20, 2020 by Sitemaster
Following last week’s approval of rucaparib (Rubraca), the US Food and Drug Administration (FDA) has now, also, approved the PARP inhibitor olaparib (Lynparza) for the treatment of men with with deleterious or suspected deleterious germline or somatic homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC) who have progressed following prior treatment with enzalutamide or abiraterone. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: castration-resistant, inhibitor, Lynparza, mCRPC, metastatic, olaparib, PARP | 1 Comment »
Posted on May 16, 2020 by Sitemaster
Yesterday evening the US Food and Drug Administration (FDA) approved rucaparib (Rubraca) for the treatment of men with BRCA1/2-mutant, metastatic, castration-resistant prostate cancer (mCRPC) who have also already been treated with androgen receptor-directed therapy and taxane-based chemotherapy. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: approval, castration-resistant, FDA, inhibitor, mCRPC, metastatic, PARP, Rubraca, rucaparib | 1 Comment »
Posted on May 1, 2020 by Sitemaster
So — rather obviously — the web has been swamped with information about COVID-19 over the past 2 months or more. That information runs the gamut from very accurate, well-constructed guidance to utter garbage, and it would have been impossible for us to sort it all out for you. So we haven’t tried. … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: coronavirus, COVID-19, pandemic | 11 Comments »
Posted on April 30, 2020 by Sitemaster
At the end of last year, Dendreon announced that the Phase III ProVent trial of sipuelucel-T (Provenge) in the treatment of men with relatively lower-risk forms of prostate cancer (as compared to active surveillance) had been fully enrolled ahead of schedule. … READ MORE …
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: active, intermediate risk, low risk, Provenge, ProVent, sipuleucel-T, surveillance, trial | Leave a comment »
Posted on April 30, 2020 by Sitemaster
A new report from a relatively small, single-institution study has provided additional information about the utility of [18F]fluciclovine (Axumin) PET/CT scans in the detection of recurrent prostate cancer after definitive first-line treatment. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: Axumin, fluciclovine, PET/CT, recurrence, scan | 2 Comments »
Posted on April 29, 2020 by Sitemaster
Alas … once again we hear that the combination of androgen receptor blockade (with enzalutamide/Xtandi) + a checkpoint inhibitor (the PD-L1 inhibitor atezolizumab/Tecentriq) has had no clinically meaningful impact on the overall survival (OS) of men with metastatic, castration-resistant prostate cancer (mCRPC) compared to enzalutamide alone. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: atezolizumab, castration-resistant, checkpoint, enzalutamide, inhibitor, mCRPC, metastatic | Leave a comment »
Posted on April 23, 2020 by Sitemaster
For the past few years, some of us have been quietly concerned about the true value of MRI scans and the accuracy of PI-RADS scores in evaluation of a patient’s risk for the presence of clinically significant prostate cancer. This is a complex issue … but data from a large, recently completed study has now validated these concerns. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: MRI, PI-RADS, risk, scan, score | 18 Comments »
Posted on April 22, 2020 by Sitemaster
According to a media release issued yesterday, Myovant Sciences (based in Basel, Switzerland) has submitted a New Drug Application (NDA) for approval of its oral LHRH antagonist, relugolix, in the treatment of men with advanced prostate cancer. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: agonist, LHRH, Myovant, oral, relugolix | 2 Comments »
Posted on April 21, 2020 by Sitemaster
TROG 01.03 RADAR, begun in 2003, was a (partly) randomized clinical trial to help optimize therapy of unfavorable-risk patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, brachy boost, dose, extent, external beam, radiation, therapy, timing | Leave a comment »
Posted on April 17, 2020 by Sitemaster
One of the questions that has been nagging at Howard Wolinsky for a while now is whether he really needs to have another biopsy … ever! … READ MORE …
Filed under: Living with Prostate Cancer, Management | Tagged: active surveillance, biopsy, low risk, monitoring, Wolinsky | 8 Comments »
Posted on April 9, 2020 by Sitemaster
A panel of top radiation oncologists in the US and the UK has addressed the question of putting off or shortening various kinds of radiation treatment (RT) for prostate cancer at a time when it is best to maintain distance from institutions that treat patients. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: coronavirus, COVID-19, radiation, therapy | Leave a comment »
Posted on March 4, 2020 by Sitemaster
Jane Brody is an experienced journalist who writes regularly about issues related to health care in The New York Times. Your sitemaster regularly reads her columns because she does her homework with care and provides sound information for her readers. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk | Tagged: active, Brody, New York Times, screening, surveillance | 4 Comments »
Posted on February 20, 2020 by Sitemaster
There’s no simple way to prevent the onset of prostate cancer or to prevent its progression over time (e.g., based on diet or taking supplements or exercising like a maniac). However, … READ MORE …
Filed under: Living with Prostate Cancer | Tagged: diet, exercise, health, living, well | Leave a comment »
Posted on February 7, 2020 by Sitemaster
So your sitemaster has been looking through the full report from the APCCC meeting held in Basel last year — as he promised he would. … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, castration-resistant, consensus, hormone-naive, hormone-sensitive, mCRPC, metastatic, mHSPC, nmCRPC, nmHSPC, non-metastatic | 2 Comments »
Posted on February 3, 2020 by Sitemaster
Last August your sitemaster attended and reported from the third iteration of the Advanced Prostate Cancer Consensus Conference (APCCC), held in Basel, Switzerland (see here, here, and here). … READ MORE …
Filed under: Drugs in development, Living with Prostate Cancer, Management, Treatment | Tagged: advanced, APCCC, conference, consensus | Leave a comment »
